Effect of caffeine on SPECT myocardial perfusion imaging during regadenoson pharmacologic stress: Rationale and design of a prospective, randomized, multicenter study

Academic Article

Abstract

  • Background: Caffeine attenuates the coronary hyperemic response to adenosine by competitive A2A receptor blockade. This study aims to determine whether oral caffeine administration compromises diagnostic accuracy in patients undergoing vasodilator stress myocardial perfusion imaging (MPI) with regadenoson, a selective adenosine A2A agonist. Methods: This multicenter, randomized, double-blind, placebo-controlled, parallel-group study includes patients with suspected coronary artery disease who regularly consume caffeine. Each participant undergoes three SPECT MPI studies: a rest study on day 1 (MPI-1); a regadenoson stress study on day 3 (MPI-2), and a regadenoson stress study on day 5 with double-blind administration of oral caffeine 200 or 400 mg or placebo capsules (MPI-3; n = 90 per arm). Only participants with 1 reversible defect on the second MPI study undergo the subsequent stress MPI test. The primary endpoint is the difference in the number of reversible defects on the two stress tests using a 17-segment model. Pharmacokinetic/ pharmacodynamic analyses will evaluate the effect of caffeine on the regadenoson exposure-response relationship. Safety will also be assessed. Conclusion: The results of this study will show whether the consumption of caffeine equivalent to 2-4 cups of coffee prior to an MPI study with regadenoson affects the diagnostic validity of stress testing (ClinicalTrials.gov number, NCT00826280). © 2010 American Society of Nuclear Cardiology.
  • Authors

    Published In

    Digital Object Identifier (doi)

    Author List

  • Tejani FH; Thompson RC; Iskandrian AE; McNutt BE; Franks B
  • Start Page

  • 73
  • End Page

  • 81
  • Volume

  • 18
  • Issue

  • 1